Skip to content

Author

D. Valcárcel

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Safety, tolerability, and pharmacokinetics (PK) of luspatercept (LUSPA) at increased injection volumes (up to 2 mL) in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) who require red blood cell (RBC) transfusions: Results from MAXILUS.

531 Background: LUSPA is approved for anemia in adults with LR-MDS who are erythropoiesis-stimulating agent (ESA)-naive or have had prior ESA failure and require RBC transfusions. At previously FDA-approved 1.2 mL syringe volume cap, LUSPA 1.75 mg/kg dosing requires multiple subcutaneous (SC) injections across...

Ali McBride, Krzysztof Mądry, Luke Fletcher et al. · 0 citations
Review Oct 2026

Molecular Underpinnings and Prevalence of Donor Cell-Derived Hematologic Neoplasms among Spanish Transplantation Centers.

Donor cell-derived hematologic neoplasm (DDHN) is defined as a de novo hematologic malignancy originated from transplanted donor stem cells, distinct from the original recipient's disease (ORD). Its prevalence and biological mechanisms remain poorly defined. We conducted a nationwide study to estimate the prevalence of...

Maria Gabarrós-Subirà, H. Pomares, F. Beas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.